Successful treatment of Helicobacter pylori-negative gastric MALT lymphoma with rituximab.

Abstract

Helicobacter pylori infection is strongly associated with low-grade gastric lymphoma, commonly known as mucosa-associated lymphoid tissue (MALT) lymphoma. H. pylori eradication leads to complete remission in 80% of early stage MALT lymphomas. The treatment for early stage H. pylori-negative gastric MALT lymphoma is evolving. Rituximab, a chimeric anti-CD20 antibody, has shown response rates of approximately 50% with minimal toxicity in patients with B-cell non-Hodgkin lymphoma. We describe herein the clinical, endoscopic, and histologic features of a patient with H. pylori-negative gastric MALT lymphoma treated successfully with rituximab.

• Authors: Nadeem Chaudhary, Howard Ozer, David Huard, Stan Lightfoot, Sikandar Mesiya
• Journal: Digestive diseases and sciences (Dig Dis Sci) Vol. 51 Issue 4 Pg. 775-8 (Apr 2006) ISSN: 0163-2116 [Print] United States
• PMID: 16615002 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents
• Rituximab

Topics

• Aged
• Antibodies, Monoclonal (administration & dosage)
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents (administration & dosage)
• Biopsy, Needle
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Follow-Up Studies
• Gastroscopy (methods)
• Helicobacter Infections (diagnosis)
• Helicobacter pylori (isolation & purification)
• Humans
• Immunohistochemistry
• Lymphoma, B-Cell, Marginal Zone (drug therapy, pathology)
• Male
• Neoplasm Staging
• Rituximab
• Stomach Neoplasms (drug therapy, pathology)
• Tomography, X-Ray Computed
• Treatment Outcome